Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entheon BiomedicalENTBF 3-1 Month Momentum % is 10.81% as of Sep. 22, 2026. Among 1,383 Biotechnology companies, Entheon Biomedical ranks better than 66.96% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Entheon Biomedical's 3-1 Month Momentum % is 10.81%.
The industry rank for Entheon Biomedical's 3-1 Month Momentum % or its related term are showing as below:
ENTBF's 3-1 Month Momentum % is ranked better than 66.96% of 1383
companies
in the Biotechnology industry
Industry Median: 0.47
vs ENTBF: 10.81
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Entheon Biomedical 3-1 Month Momentum % Related Terms
ENTBF vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Entheon Biomedical's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entheon Biomedical 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entheon Biomedical's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Entheon Biomedical's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entheon Biomedical (ENTBF) has a 3-1 Month Momentum % of 10.81% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Entheon Biomedical and its competitors. According to the industry distribution chart, Entheon Biomedical ranks #457 out of 1383 companies in the Biotechnology industry, placing it in the top 33%.
Is Entheon Biomedical's 3-1 Month Momentum % too high?
Entheon Biomedical's current 3-1 Month Momentum % is 10.81%. The Biotechnology industry median 3-1 Month Momentum % is 0.47. Entheon Biomedical's value of 10.81% is 2200% above this industry median. Based on the distribution chart, Entheon Biomedical ranks #457 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entheon Biomedical's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entheon Biomedical ranks #457 out of 1383 companies for 3-1 Month Momentum %. This puts Entheon Biomedical in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.47. Entheon Biomedical's value of 10.81% is 2200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.47, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entheon Biomedical's current 3-1 Month Momentum % of 10.81% is 2200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Entheon Biomedical and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entheon Biomedical's current 3-1 Month Momentum % is 10.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current 3-1 Month Momentum % of 10.81%. The current 3-1 Month Momentum % is 10.81% and 2200% above the Biotechnology industry median of 0.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current 3-1 Month Momentum % is 10.81% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entheon Biomedical Corp. is a Canadian biotechnology company focused on developing psychedelic-based therapeutic treatments for addiction and substance use disorders. Its lead program centers on DMT (dimethyltryptamine), a naturally occurring psychedelic compound, which the company is investigating as an adjunct to psychotherapy for conditions such as opioid use disorder and other addictive behaviors. Entheon's approach combines proprietary drug formulations with clinical protocols and digital tools intended to support supervised treatment. The company operates in the emerging psychedelics-assisted therapy sector, targeting healthcare providers, clinics, and patients in jurisdictions where such treatments are permitted. As a clinical-stage enterprise, Entheon does not yet generate product revenue; its activities are funded through equity financing and partnerships, with value tied to the progress of its research programs through preclinical and clinical development toward regulatory approval.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTBF has been successfully added to your 
